Share on StockTwits

United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 9,066 shares of the company’s stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $98.48, for a total value of $892,819.68. Following the completion of the transaction, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $13,787. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of United Therapeutics (NASDAQ:UTHR) traded down 2.06% on Friday, hitting $96.20. 815,235 shares of the company’s stock traded hands. United Therapeutics has a 52 week low of $59.05 and a 52 week high of $116.65. The stock has a 50-day moving average of $96.52 and a 200-day moving average of $95.88. The company has a market cap of $4.856 billion and a price-to-earnings ratio of 29.95.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $2.88 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.51 by $1.37. The company had revenue of $289.02 million for the quarter, compared to the consensus estimate of $295.43 million. Analysts expect that United Therapeutics will post $6.93 EPS for the current fiscal year.

A number of research firms have recently commented on UTHR. Analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock. Separately, analysts at Zacks downgraded shares of United Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Friday, April 4th. They now have a $98.00 price target on the stock. Finally, analysts at Wedbush raised their price target on shares of United Therapeutics from $114.00 to $119.00 in a research note on Wednesday, April 2nd. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $95.50.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.